Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?

Morris, 2017, Int J Radiat Oncol Biol Phys, 98, 275, 10.1016/j.ijrobp.2016.11.026 Wang, 2020, The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis, World J Surg Oncol, 18, 42, 10.1186/s12957-020-01824-9 Lai, 1991, The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: The radiation therapy oncology group 75–06 and 77–06 experience, Int J Radiat Oncol Biol Phys, 21, 925, 10.1016/0360-3016(91)90731-I Dong, 2018, Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer, J Med Imag Radiat Oncol, 62, 116, 10.1111/1754-9485.12675 Amdur, 1990, Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up, Radiother Oncol, 18, 235, 10.1016/0167-8140(90)90059-6 Liauw, 2011, Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer, Int J Radiat Oncol Biol Phys, 81, 751, 10.1016/j.ijrobp.2010.06.054 Murphy, 2016, Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States, J Clin Oncol, 34, 169, 10.1200/JCO.2015.61.5906 Chen, 2000, The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer, Lung Cancer, 28, 11, 10.1016/S0169-5002(99)00113-0 Perez, 1995, Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy, Int J Radiat Oncol Biol Phys, 32, 1275, 10.1016/0360-3016(95)00220-S Graf, 2003, Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy, Oncology, 65, 14, 10.1159/000071200 McMillan, 2017, Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer, Int J Radiat Oncol Biol Phys, 98, 1142, 10.1016/j.ijrobp.2017.04.004 Vogelius, 2013, Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?, Int J Radiat Oncol Biol Phys, 85, 89, 10.1016/j.ijrobp.2012.03.004 Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-Fractionation Sensitivity of Prostate Cancer Deduced from Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9-2.2) Gy; 2012. doi:10.1016/j.ijrobp.2010.10.075. Spratt, 2016, Identification and Validation of Intrinsic Subtypes of Prostate Cancer, Int J Radiat Oncol • Biol • Phys, 96, S3, 10.1016/j.ijrobp.2016.06.025 Hasan, 2019, Optimal timing of thoracic radiotherapy in limited stage small cell lung cancer (SCLC) with daily fractionation: A brief report, Radiother Oncol, 132, 23, 10.1016/j.radonc.2018.11.005 Austin, 2011, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies, Multivar Behav Res, 46, 399, 10.1080/00273171.2011.568786 Kishan, 2018, Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9–10 prostate cancer, JAMA - J Am Med Associat, 319, 896, 10.1001/jama.2018.0587 Alpha-Beta Ratio - an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/alpha-beta-ratio. Accessed May 7, 2020. Cosset, 2019, Which alpha/beta ratio for prostate cancer in 2019?, Cancer/Radiotherapie Malone, 2020, Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: A Phase III randomized controlled trial, J Clin Oncol, 38, 593, 10.1200/JCO.19.01904 Robbins, 2007, Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995–2004, Cancer, 110, 1255, 10.1002/cncr.22872 Man, 2003, Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer, J Urol, 170, 901, 10.1097/01.ju.0000081423.37043.b4 Mahal, 2016, National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study, Cancer, 122, 1505, 10.1002/cncr.29960 Roach, 1992, The prognostic significance of race and survival from prostate cancer based on patients irradiated on radiation therapy oncology group protocols (1976–1985), Int J Radiat Oncol Biol Phys, 24, 441, 10.1016/0360-3016(92)91058-U Dess, 2019, Association of Black Race with Prostate Cancer-Specific and Other-Cause Mortality, JAMA Oncol, 5, 975, 10.1001/jamaoncol.2019.0826 Radiation therapy outcomes better for African-American prostate cancer patients than Caucasian patients - American Society for Radiation Oncology (ASTRO) - American Society for Radiation Oncology (ASTRO). https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2018/Radiation-therapy-outcomes-better-for-African-Amer. Accessed May 7; 2020. Polite, 2017, Charting the future of cancer health disparities research: A position statement from the American association for cancer research, the American cancer society, the American society of clinical oncology, & the national cancer institute, J Clin Oncol, 35, 3075, 10.1200/JCO.2017.73.6546 Dearnaley, 2014, Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial, LancetOncol, 15, 464 Zelefsky, 2006, Long-Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer, J Urol, 176, 1415, 10.1016/j.juro.2006.06.002 Eisenstein, 2019, The declining art of brachytherapy, Nature, 574, S81, 10.1038/d41586-019-03275-z Morgan SC, Hoffman K, Andrew Loblaw D, et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Conflict of Interest Disclosure Statement.; 2018. Incrocci, 2016, Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, LancetOncol, 17, 1061 Catton, 2017, Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer, J Clin Oncol, 35, 1884, 10.1200/JCO.2016.71.7397 Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, LancetOncol, 17, 1047 Lee, 2016, Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer, J Clin Oncol, 34, 2325, 10.1200/JCO.2016.67.0448 Stokes, 2017, Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis, Pract Radiat Oncol, 7, 270, 10.1016/j.prro.2017.03.011